Polari Group
The Polari Group feels that the sexual health and wellness industry should be inclusive and that the future of sexual health will focus on anorectal health. Currently, preparing for anorectal intercourse can take up to an hour by using a process called anal douching. This can hinder spontaneity, impact relationships, and raise the risk of sexually transmitted infections. Our team is creating innovative products to simplify the preparation for anorectal intercourse and make sex more spontaneous.
The Polari Group feels that the sexual health and wellness industry should be inclusive and that the future of sexual health will focus on anorectal health. Currently, preparing for anorectal intercourse can take up to an hour by using a process called anal douching. This can hinder spontaneity, impact relationships, and raise the risk of sexually transmitted infections. Our team is creating innovative products to simplify the preparation for anorectal intercourse and make sex more spontaneous.
Polari Group has raised $540k across 1 round. Its most recent round was a Pre-Seed of $540k in Jun 2024. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Polari Group is featured in
Similar companies
Native Labs is a platform using AI to improve efficiency and scalability in the manufacturing of Cell and Gene Therapy. Through our collaboration with manufacturers, we have created a secure and flexible platform that utilizes AI-powered workflows to help unlock the potential of manufacturing data, quickly generate and analyze high-quality data, and improve communication between different teams. Our platform is easy to deploy, requires no training, and can easily be integrated into existing workflows. We are currently working with therapy developers to streamline and future-proof their manufacturing processes. Contact us for more information or to inquire about joining our beta testing program.
Avidicure is leading the way in developing a new type of antibody treatment called "AVC-Boosters", which have dual agonistic capabilities and are engineered for increased avidity. These antibodies are designed to effectively and safely deliver potent monotherapy for cancer treatment, with a wide range of potential uses in the field of oncology.
It specializes in developing innovative cell therapies, with a primary focus on addressing neonatal brain injuries caused by hypoxic-ischemic encephalopathy (HIE). This condition, resulting from oxygen deprivation during or shortly after birth, is a leading cause of neonatal deaths and long-term neurological impairments, such as cerebral palsy and epilepsy.
Orange Grove Bio (OGB) is a platform that specializes in investing and developing preclinical drugs, with the aim of decreasing the expenses associated with discovering medications and expediting their progression into clinical trials.
The Verschuren Centre assists in the advancement of sustainable technologies for cleantech companies and supports their efforts to enter the market.
Fresh Inset Vision aims to conserve fresh produce resources by implementing advanced Vidre+ technology that effectively preserves product freshness during the entire supply chain, from the packer/shipper to the final consumer.
FibroBiologics is a regenerative medicine firm situated in Houston, Texas that is working on an inventive approach to treat chronic diseases using fibroblast cells. Their innovative research spans across several clinical pathways such as Disc Degeneration, Orthopedics, Multiple Sclerosis, and Cancer, and is supported by over 150 U.S. and International patents that have either been issued or are still pending. FibroBiologics' work stands as a testament to the development of cell therapy and represents the future of medical advancement.
A new class of programmable polymer nanoparticles is being developed by Nanite, a next-generation non-viral gene delivery business, for a variety of applications and indications. The business' AI-driven SAYER platform combines state-of-the-art, high-throughput experimental and computational methodologies to create delivery systems that are appropriate for their intended use and transport a variety of genetic cargoes with tissue selectivity.
a nonprofit organisation dedicated to reducing greenhouse gas emissions by genetically increasing CO2 collection and storage in trees
Love Lifesciences is creating a line of injection safety tools that will enhance patient comfort when administering injection drugs. The injection procedure is time-consuming, risky for unneeded pain, and typically causes worry and panic. The current injection approach also leaves a lot of possibility for error in terms of dosage and needle stick injuries. Since the procedure can be so unpleasant, people frequently refuse or stop using these injectable therapy choices. When these issues are present together, patients experience worse health outcomes. Our revised injection process gives patients full injection control while reducing the chance of error. Unnecessary fear, worry, and discomfort shouldn't interfere with patient treatment in any way.
Empatica is a startup that specializes in emotional computing and human data analytics. We create ground-breaking wearable technology with superior medical sensing. Our system consists of a pair of wristbands, software for desktop and smartphone computers, and real-time syncing with a cloud computing service.
Cybele utilizes unique technology to deliver high-effective solutions for human health.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.